

Ergomed PLC

02:26 14 Oct 2016

Ergomed celebrates fourth licensing deal for anti-cancer compound

Clinical services specialist Ergomed Plc (LON:ERGO) said its co-development partner AEterna Zentaris Inc (TSE:AEX, NASDAQ:AEZS) has signed an additional licensing deal for cancer drug Zoptrex.

AEterna Zentaris signed an exclusive licence agreement with Specialised Therapeutics Asia for Zoptrex, covering the territories of Australia and New Zealand. It is the fourth licensing agreement for AEterna's lead anti-cancer compound.

AEterna will receive an up-front payment plus milestone payments and royalties, while Ergomed will receive a portion of all revenues generated from the commercialisation of the product.

Zoptrex is currently in a fully-enrolled Phase 3 clinical trial for patients with cancer of the womb or uterus. If the results of the trial warrant doing so, AEterna will submit a new drug application for Zoptrex to the United States Food and Drug Administration in 2017.

"This licensing agreement for Australia and New Zealand adds another two territories to the overall coverage now for Zoptrex and demonstrates the value of our co-development business," said Dr Miroslav Reljanovic.

"In line with our strategy to expand our co-development business, we also recently announced a new partnership, which, together with this licensing agreement, further validates our hybrid business model," he added.

Price: 850

Market Cap: £414.1 m

1 Year Share Price Graph



Share Information

Code: ERGO

Listing: AIM

52 week	High	Low
	860	258

Sector: Pharma & Biotech

Website: www.ergomedplc.com

Company Synopsis:

Ergomed plc is dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs. Operating with a global footprint in over 65 countries, Ergomed enables our clients to access solutions even for their toughest clinical development and trial management challenges from early phase to complex late stage programmes.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Ergomed PLC named herein, including the promotion by the Company of Ergomed PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).